Markers and methods for assessing and treating Crohn's and related disorders
A method for assessment of the suitability of and/or effectiveness of a target therapy for a gastrointestinal-related disorder, such as Crohn's disease, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 10-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies.
1. A method for predicting the suitability of treatment with an anti-IL-12 antibody therapy for Crohn's disease in a subject, comprising:
a) preparing a sample of nucleic acids from a specimen obtained from the subject;
b) contacting the sample with a panel of nucleic acid segments consisting of at least a portion of the nucleotide sequences corresponding to SEQ ID NOS:1-10 to detect levels of the panel segments;
c) evaluating the sample against a reference standard to determine the magnitude of change in the amounts of the portions of the nucleotide sequences present in the sample;
d) correlating the magnitude of change with the suitability of treatment with anti-IL-12 antibody therapy for Crohn's disease; and
e) treating or refraining from treating the subject based on the correlation of suitability of treatment.
2. The method of claim 1 , wherein the anti-IL-12 antibody is CNTO1275.
3. The method of claim 1 , wherein the reference standard is from a colon biopsy, serum, or plasma from an untreated Crohn's disease patient, a responder to the anti-IL-12 antibody therapy, or a non-responder to the anti-IL-12 antibody therapy.
4. The method of claim 1 , wherein the collection is an array of nucleic acid segments.
5. The method of claim 1 , wherein the evaluating step comprises evaluating the sample against a reference standard and determining whether the average intensity value for each of the members of the panel is equal to or above X or below Y.
6. The method of claim 5 , wherein the average intensity value for each of the members of the panel being equal to or above X indicates the subject will be a responder to the target therapy and the average intensity value for each of the members of the panel being below Y indicates the subject will be a non-responder.
7. The method of claim 1 , wherein the sample is from a patient providing the sample prior to administration of a therapy.
8. The method of claim 1 , wherein at least one member from the panel is selected from the group consisting of genes for cytokines, chemokines, proteins involved in extracellular matrix remodeling, angiogenesis associated growth factors, a cell adhesion molecule, and a myeloperoxidase.
9. The method of claim 1 , wherein the specimen comprises plasma or serum from a subject.